Financial Advocates Investment Management Increases Stake in Johnson & Johnson (NYSE:JNJ)

Financial Advocates Investment Management grew its holdings in Johnson & Johnson (NYSE:JNJ) by 12.8% in the 4th quarter, HoldingsChannel.com reports. The fund owned 21,029 shares of the company’s stock after buying an additional 2,380 shares during the quarter. Financial Advocates Investment Management’s holdings in Johnson & Johnson were worth $3,041,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the stock. Adero Partners LLC lifted its stake in Johnson & Johnson by 19.0% in the fourth quarter. Adero Partners LLC now owns 13,233 shares of the company’s stock worth $1,914,000 after acquiring an additional 2,116 shares during the last quarter. YANKCOM Partnership acquired a new position in shares of Johnson & Johnson during the fourth quarter worth $923,000. Centennial Wealth Advisory LLC increased its holdings in Johnson & Johnson by 11.6% in the fourth quarter. Centennial Wealth Advisory LLC now owns 1,968 shares of the company’s stock valued at $285,000 after buying an additional 204 shares during the last quarter. NovaPoint Capital LLC lifted its holdings in Johnson & Johnson by 4.0% during the 4th quarter. NovaPoint Capital LLC now owns 24,914 shares of the company’s stock worth $3,603,000 after buying an additional 953 shares during the last quarter. Finally, Robertson Stephens Wealth Management LLC boosted its position in shares of Johnson & Johnson by 9.2% during the 4th quarter. Robertson Stephens Wealth Management LLC now owns 31,105 shares of the company’s stock worth $4,498,000 after acquiring an additional 2,632 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In related news, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the transaction, the director now owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

JNJ has been the subject of several recent analyst reports. Morgan Stanley decreased their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Raymond James lowered their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Guggenheim lifted their price target on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a research note on Monday, February 3rd. Citigroup decreased their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Nine equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Trading Down 0.3 %

Shares of Johnson & Johnson stock opened at $153.10 on Monday. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm has a market cap of $368.61 billion, a price-to-earnings ratio of 23.02, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company’s 50-day simple moving average is $147.42 and its 200-day simple moving average is $156.08.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same period in the prior year, the business posted $2.29 EPS. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be issued a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.24%. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.